The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

中文翻译：

---

KRAS 等位基因失衡：数量上的优势和劣势

事实证明，突变 KRAS 肿瘤的治疗脆弱性的识别很难实现。Burgess 及其同事最近在 Cell 上报告说，突变/野生型 Kras 等位基因剂量决定了白血病模型中的克隆适应性和 MEK 抑制剂敏感性，这表明 KRAS 等位基因失衡可能是一个重要且被忽视的变量。